Sandy Spring Bank’s Sage Therapeutics SAGE Stock Holding History

Sandy Spring Bank’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$795	Hold	100	–	–	﹤0.01%	1105
2024 Q4	$543	Hold	100	–	–	﹤0.01%	1133
2024 Q3	$722	Hold	100	–	–	﹤0.01%	1110
2024 Q2	$1.09K	Hold	100	–	–	﹤0.01%	1147
2024 Q1	$1.87K	Hold	100	–	–	﹤0.01%	1058
2023 Q4	$2.17K	Hold	100	–	–	﹤0.01%	1012
2023 Q3	$2.06K	Hold	100	–	–	﹤0.01%	1023
2023 Q2	$4.7K	Hold	100	–	–	﹤0.01%	961
2023 Q1	$4.2K	Hold	100	–	–	﹤0.01%	950
2022 Q4	$3.81K	Hold	100	–	–	﹤0.01%	961
2022 Q3	$4K	Hold	100	–	–	﹤0.01%	962
2022 Q2	$3K	Hold	100	–	–	﹤0.01%	1020
2022 Q1	$3K	Hold	100	–	–	﹤0.01%	1033
2021 Q4	$4K	Hold	100	–	–	﹤0.01%	1061
2021 Q3	$4K	Hold	100	–	–	﹤0.01%	1001
2021 Q2	$6K	Hold	100	–	–	﹤0.01%	966
2021 Q1	$7K	Hold	100	–	–	﹤0.01%	848
2020 Q4	$9K	Hold	100	–	–	﹤0.01%	766
2020 Q3	$6K	Hold	100	–	–	﹤0.01%	737
2020 Q2	$4K	Buy	+100	New	+$3.63K	﹤0.01%	785

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Sandy Spring Bank's SAGE Position: Q1 2025 in Review

Sandy Spring Bank held its Sage Therapeutics (SAGE) position steady in Q1 2025 at 100 shares worth $795. The position accounts for ﹤0.01% of the portfolio, ranked #1105.

Sandy Spring Bank first reported a position in SAGE in Q2 2020 and has held it in 20 quarters since. The position peaked at $9K in Q4 2020. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

Sandy Spring Bank held 100 shares of Sage Therapeutics worth $795 as of Q1 2025.
Sandy Spring Bank left its Sage Therapeutics share count unchanged in Q1 2025.
Sage Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1105 holding.
Sandy Spring Bank first reported a position in Sage Therapeutics in Q2 2020 and has held it in 20 quarters since.
Sandy Spring Bank's Sage Therapeutics position peaked at $9K in Q4 2020.
198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.